Japan Pharma - Top Picks
While Gni Group Ltd (2160 JP) is our high risk-high return pick, Mitsubishi Tanabe Pharma (4508 JP) is a contrarian call in anticipation of value...
543 Views
Japan: Fortnightly Update - And So It Goes
AND SO IT GOES - After our eight-day 4.5% 'Thanksgiving rally', the market reverted to recent type and promptly fell 6.5% to Tuesday's low, which...
423 Views
Independent Director Is a Great Way to Supplement Retirement in Japan....
We all know that Japan has tried to give the impression that they are improving corporate governance. However, when you start to dig into the...
492 Views
Taisho 1H FY18 (YE Mar'19) Results - First Glance
Key highlights “Prescription pharma” segment (-15.1% to ¥~40b) lead overall sales decline by 6.6% to ¥129.5b Y-o-y decrease in SG&A and R&D...
302 Views
Japan Pharma: Core Coverage Investment Thesis and Valuations (III/III)
Takeda Pharmaceutical (4502 JP), Astellas Pharma (4503 JP), Daiichi Sankyo (4568 JP), Eisai Co Ltd (4523 JP), Otsuka Holdings (4578 JP), Chugai...
318 Views